|
| Index | - | P/E | - | EPS (ttm) | -0.30 | Insider Own | 0.10% | Shs Outstand | 37.68M | Perf Week | 12.20% |
| Market Cap | 68.10M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 21.21M | Perf Month | 8.24% |
| Income | -11.10M | PEG | - | EPS next Q | - | Inst Own | 18.30% | Short Float | 4.25% | Perf Quarter | 5.14% |
| Sales | 1.90M | P/S | 35.84 | EPS this Y | -51.80% | Inst Trans | -10.89% | Short Ratio | 3.15 | Perf Half Y | 92.17% |
| Book/sh | -0.10 | P/B | - | EPS next Y | - | ROA | -207.10% | Target Price | - | Perf Year | 2.79% |
| Cash/sh | 0.03 | P/C | 61.91 | EPS next 5Y | - | ROE | 964.50% | 52W Range | 0.67 - 3.93 | Perf YTD | 21.05% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -343.40% | 52W High | -53.18% | Beta | - |
| Dividend % | - | Quick Ratio | 0.40 | Sales past 5Y | - | Gross Margin | 89.60% | 52W Low | 176.28% | ATR | 0.11 |
| Employees | 17 | Current Ratio | 0.40 | Sales Q/Q | 0.00% | Oper. Margin | - | RSI (14) | 61.32 | Volatility | 8.26% 5.83% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | 21.10% | Profit Margin | - | Rel Volume | 1.26 | Prev Close | 1.94 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 286.77K | Price | 1.84 |
| Recom | - | SMA20 | 11.58% | SMA50 | 11.28% | SMA200 | 54.89% | Volume | 362,140 | Change | -5.15% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite